查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1954674

全球病毒清除市场：市场规模、占有率、成长率、产业分析、依类型、应用和地区划分的考察、未来预测（2026-2034）

Viral Clearance Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 128 Pages | 商品交期: 请询问到货日

价格

病毒清除市场成长驱动因素

2025年全球病毒清除市场规模为8.341亿美元，预计将从2026年的9.7165亿美元成长到2034年的38.0475亿美元，在预测期（2026-2034年）内年复合成长率高达18.60%。北美地区凭藉其成熟的生物技术生态系统和不断成长的临床试验活动，在2025年占据了37.50%的市场占有率，成为市场主导者。

病毒清除检测对于植物、动物或人源生物製品的研发和生产非常重要，因为这些产品极易受到病毒污染的影响。这些检测可确保疫苗、重组蛋白、血液製品以及细胞和基因疗法的安全性和纯度。随着全球疫苗年产量达到约50亿剂，对病毒安全性检测的需求持续成长。儘管新冠疫情封锁期间市场成长放缓，但2021年的復苏得益于疫苗研发和临床研究的增加。

市场动态

市场驱动因素

生物製药研发投入增加

随着心血管疾病、癌症和糖尿病等慢性疾病的日益增多，对生物製剂的需求也不断成长。根据世界卫生组织统计，2020年全球有1,000万人死于癌症。为了应对这项挑战，製药公司增加研发投入。例如，美国药品研究与製造商协会（PhRMA）成员公司在2022年投入了1,023亿美元研发。由于病毒清除是生物製药产品核准的必要条件，研发投入的增加直接推动了相关服务的需求。

严格的监理要求

包括国际人用药品註册技术协调会（ICH）在内的全球监管机构已发布了针对生物技术产品病毒安全性评估的严格指南。符合新药研究申请（IND）和生物製品许可申请（BLA）的提交标准，使得病毒清除检测成为生物製品开发的关键环节，推动了市场成长。

市场趋势

主要公司扩建设施

主要服务供应商扩大其病毒清除检测设施，以满足不断成长的全球需求。例如，2022年9月，Merck KGaA在中国开设了一家病毒清除检测中心，作为其生物製品检测中心的一部分。同样，WuXi Biologics和Texcell等公司也在扩大其检测设施，以提升服务能力。这些扩建有助于製药和生物技术公司更佳获取检测资源，并支持疫苗和先进疗法的快速研发。

限制因子

先进技术成本高

病毒清除检测需要先进的分析系统，例如色谱法和高效液相层析法（HPLC）。设备成本可能在3万美元到10万美元之间，对小型企业来说是一笔不小的开销。此外，对高技能科学家的竞争推高了营运成本，限制了小型供应商的采用。

市场区隔分析

依方法划分

该市场依方法分为三类：病毒去除、病毒灭活和病毒检测。

到2026年，病毒去除领域将成为市场成长的主要驱动力。这得益于疫苗和生物製剂需求的成长以及研发投入的强劲。色谱和过滤等技术因其高效性而广泛采用。

病毒灭活领域预计将保持稳定成长，这得益于血浆蛋白和基因治疗产品获准数量的增加。另一方面，包括PCR和次世代定序（NGS）在内的病毒检测方法预计将以相当可观的年复合成长率成长，因为它们在识别病毒污染物方面发挥着非常重要的作用。

依应用领域划分

依应用领域划分，市场包括疫苗、血液及血液製品、重组蛋白、细胞及基因治疗产品等产品。

预计到2026年，疫苗领域将成为市场成长的主要驱动力，这主要得益于疫苗接种率的提高以及人们对传染病和慢性病防护需求的不断成长。例如，2022年全球麻疹疫苗接种率达83%。

预计血液及血液製品领域将显着成长，这主要得益于全球每年约1.185亿份的捐血量。由于先进疗法在罕见疾病和慢性病治疗中的应用日益广泛，细胞和基因治疗领域预计将以最高的年复合成长率成长。

依最终使用者划分

该市场依最终用户细分为製药和生物技术行业、合约研究组织（CRO）、学术和研究机构以及其他。

2026年，製药和生技产业将成为市场的主要驱动力。这主要是由于生物製品生产中强制性的病毒安全性检测。由于检测服务外包的增加，CRO预计将显着成长。受药物研发计画的扩展推动，学术和研究机构预计也将强劲成长。

区域洞察

北美

2025年，北美市场规模将达到3.127亿美元，凭藉强大的製药生产能力和不断成长的临床试验，继续保持领先地位。在美国，註册临床试验的数量从2010年的7462项增加到2022年的9901项，这增强了对病毒清除服务的需求。

欧洲

欧洲是第二大市场，这得益于其强大的生物技术基础和不断成长的研发投入。例如，CRISPR Therapeutics等公司在2022年投资了4.616亿美元用于研发，推动了该地区的扩张。

亚太地区

由于仿製药产量增加、医学研究经费投入增加以及合约研究组织（CRO）的扩张，亚太地区预计将经历快速成长。中国和日本加强其国内生物製药产能，推动对病毒清除服务的需求。

由于医疗支出增加和生物製品应用范围扩大，拉丁美洲和中东及非洲地区预计将实现温和成长。

目录

第1章 引言

第2章 执行摘要

第3章 市场动态

  • 市场驱动因素
  • 市场限制因素
  • 市场机会

第4章 主要考察

  • 技术进步
  • 主要行业趋势
  • 监理环境
  • 主要产业趋势：併购、业务合作关係等
  • 新冠疫情对市场的影响

第5章 全球病毒清除市场分析：洞察与预测（2021-2034）

  • 市场分析、洞察与预测：依方法划分
    • 病毒去除法
      • 色谱法
      • 过滤法
      • 沉淀法
    • 病毒灭活方法
      • pH调节法
      • 溶剂/洗涤剂法（S/D）
      • 巴氏杀菌法
      • 干热法
      • 其他
    • 病毒检测方法
      • 次世代定序（NGS）
      • 聚合酶炼式反应（PCR）
      • 体内检测
      • 体外检测检测
      • 其他
  • 市场分析、洞察与预测：依应用领域划分
    • 血液及血液製品
    • 重组蛋白
    • 细胞及基因治疗产品
    • 疫苗
    • 其他
  • 市场分析、洞察与预测：依最终用户划分
    • 製药及生技产业
    • 学术及研究机构
    • 合约研究组织（CRO）
    • 其他
  • 市场分析、洞察与预测：依地区划分
    • 北美
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东及非洲

第6章 北美病毒清除市场分析、洞察与预测（2021-2034）

  • 依国家划分
    • 美国
    • 加拿大

第7章 欧洲病毒清除市场分析、洞察与预测（2021-2034）

  • 依国家划分
    • 英国
    • 德国
    • 法国
    • 西班牙
    • 义大利
    • 斯堪的纳维亚
    • 其他欧洲地区

第8章 亚太地区病毒清除市场分析、洞察与预测（2021-2034）

  • 依国家划分
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 东南亚亚洲
    • 其他亚太地区

第9章 拉丁美洲病毒清除市场分析、洞察与预测（2021-2034）

  • 依国家划分
    • 巴西
    • 墨西哥
    • 其他拉丁美洲国家

第10章 中东与非洲病毒清除市场分析、洞察与预测（2021-2034）

  • 依国家划分
    • GCC
    • 南非
    • 其他中东和非洲国家

第11章 竞争分析

  • 全球市场占有率分析（2025）
  • 公司简介
    • Merck KGaA
    • Wuxi Biologics
    • Charles River Laboratories
    • Texcell
    • Vironova
    • Kedrion
    • Clean Cells
    • ViruSure GmbH
    • Sartorius AG
    • Syngene International Limited
    • Microbiologics
Product Code: FBI105611

Growth Factors of viral clearance Market

The global viral clearance market size was valued at USD 834.1 million in 2025 and is projected to grow from USD 971.65 million in 2026 to USD 3,804.75 million by 2034, exhibiting a strong CAGR of 18.60% during the forecast period (2026-2034). North America dominated the market with a 37.50% share in 2025, supported by a well-established biotechnology ecosystem and rising clinical trial activity.

Viral clearance studies are critical in the development and manufacturing of biologics derived from plants, animals, or humans, as these products are highly susceptible to viral contamination. These studies ensure the safety and purity of vaccines, recombinant proteins, blood products, and cell & gene therapies. With global vaccine production reaching nearly 5.0 billion doses annually, the demand for viral safety testing continues to increase. Although the market witnessed slower growth during the COVID-19 lockdown phase, recovery in 2021 was driven by increased vaccine development and clinical research.

Market Dynamics

Market Drivers

Rising Biopharmaceutical R&D Expenditure

The growing burden of chronic diseases such as cardiovascular disorders, cancer, and diabetes has intensified the need for biologics. According to WHO, cancer accounted for 10 million deaths globally in 2020. To address this, pharmaceutical companies are increasing R&D spending. For instance, PhRMA member companies invested USD 102.3 billion in R&D in 2022. As viral clearance is mandatory for biologics approval, increasing R&D directly fuels demand for these services.

Stringent Regulatory Requirements

Global regulatory bodies, including the International Council for Harmonisation (ICH), have issued strict guidelines on viral safety evaluation for biotechnology products. Compliance with IND and BLA submission standards has made viral clearance testing an essential part of biologics development, thereby driving market growth.

Market Trends

Facility Expansion by Key Players

Leading service providers are expanding viral clearance laboratories to meet growing global demand. For example, in September 2022, Merck KGaA opened a viral clearance laboratory in China as part of its Biologics Testing Center. Similarly, companies such as WuXi Biologics and Texcell have expanded testing facilities to enhance service capabilities. These expansions improve accessibility for pharmaceutical and biotech firms and support the rapid development of vaccines and advanced therapies.

Restraining Factors

High Cost of Advanced Technologies

Viral clearance studies require sophisticated analytical systems such as chromatography and high-performance liquid chromatography (HPLC). Equipment costs can range from USD 30,000 to USD 100,000, creating financial barriers for smaller firms. Additionally, competition for highly skilled scientists increases operational costs, limiting adoption among small-scale providers.

Segmentation Analysis

By Method

The market is segmented into viral removal, viral inactivation, and viral detection.

The viral removal method segment dominated in 2026, driven by increasing demand for vaccines and biologics and strong R&D investments. Techniques such as chromatography and filtration are widely used due to their efficiency.

The viral inactivation segment is projected to grow steadily, supported by rising approvals of plasma proteins and gene therapy products. Meanwhile, viral detection methods, including PCR and next-generation sequencing (NGS), are expected to grow at a considerable CAGR due to their essential role in identifying viral contaminants.

By Application

Based on application, the market includes vaccines, blood & blood products, recombinant proteins, cellular & gene therapy products, and others.

The vaccines segment dominated in 2026, fueled by growing immunization coverage and demand for protection against infectious and chronic diseases. For example, global measles vaccine coverage increased to 83% in 2022.

The blood & blood products segment is anticipated to expand substantially, supported by approximately 118.5 million blood donations collected worldwide annually. The cellular & gene therapy segment is expected to grow at the highest CAGR due to increasing use of advanced therapies in treating rare and chronic conditions.

By End-user

The market is segmented into pharmaceutical & biotech industry, CROs, academic research institutes, and others.

The pharmaceutical & biotech industry segment dominated in 2026, as viral safety testing is mandatory for biologics manufacturing. CROs are projected to grow significantly due to increased outsourcing of testing services. Academic and research institutes are also expected to witness strong growth, driven by expanding drug discovery research initiatives.

Regional Insights

North America

North America accounted for USD 312.7 million in 2025, maintaining leadership due to strong pharmaceutical manufacturing capacity and increasing clinical trials. The U.S. recorded a rise in registered clinical trials from 7,462 in 2010 to 9,901 in 2022, strengthening demand for viral clearance services.

Europe

Europe is the second-largest market, supported by a strong biotechnology foundation and rising R&D spending. Companies such as CRISPR Therapeutics invested USD 461.6 million in R&D in 2022, contributing to regional expansion.

Asia Pacific

Asia Pacific is projected to grow rapidly due to increased generics manufacturing, funding for medical research, and expansion of CROs. China and Japan are strengthening domestic biopharmaceutical production capabilities, boosting demand for viral clearance services.

Latin America and the Middle East & Africa are expected to witness gradual growth due to rising healthcare expenditure and biologics adoption.

Competitive Landscape

Key market players include Merck KGaA, Charles River Laboratories, WuXi Biologics, Texcell, Sartorius AG, Kedrion, Clean Cells, ViruSure GmbH, and Syngene International. These companies focus on facility expansion, acquisitions, and service portfolio enhancement to strengthen market presence.

Recent developments include:

  • June 2023: Texcell expanded its viral clearance facility in the U.S.
  • December 2022: WuXi Biologics opened a Biosafety Testing Center in Shanghai.
  • December 2021: ViruSure acquired Bionique Testing Laboratories to enhance service offerings.

Conclusion

The global viral clearance market is poised for robust expansion, growing from USD 834.1 million in 2025 to USD 971.65 million in 2026, and projected to reach USD 3,804.75 million by 2034, at a remarkable CAGR of 18.60%. Increasing biologics development, stringent regulatory requirements, expanding R&D investments, and facility expansions by key players are primary growth drivers. Despite high technology costs and talent shortages, the rising global demand for safe and effective biopharmaceuticals will continue to propel long-term market growth.

Segmentation By Method

  • Viral Removal Method
    • Chromatography
    • Filtration
    • Precipitation
  • Viral Inactivation Method
    • pH Modification
    • Solvent Detergent (S/D)
    • Pasteurization
    • Dry Heat
    • Others
  • Viral Detection Method
    • Next Generation Sequencing (NGS)
    • Polymerase Chain Reaction (PCR)
    • In vivo Assay
    • In vitro Assay
    • Others

By Application

  • Blood and Blood Products
  • Recombinant Proteins
  • Cellular & Gene Therapy Products
  • Vaccines
  • Others

By End-user

  • Pharmaceutical and Biotech Industry
  • Academic Research Institutes
  • CROs
  • Others

By Geography

  • North America (By Method, Application, End-user, and Country)
    • U.S.
    • Canada
  • Europe (By Method, Application, End-user, and Country/Sub-region)
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Method, Application, End-user, and Country/Sub-region)
    • China
    • India
    • Japan
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Method, Application, End-user, and Country/Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Method, Application, End-user, and Country/Sub-region)
    • South Africa
    • GCC
    • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities

4. Key Insights

  • 4.1. Technological Advancements
  • 4.2. Key Industry Trends
  • 4.3. Regulatory Scenario
  • 4.4. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
  • 4.5. Impact of COVID-19 on the Market

5. Global Viral Clearance Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Method
    • 5.1.1. Viral Removal Method
      • 5.1.1.1. Chromatography
      • 5.1.1.2. Filtration
      • 5.1.1.3. Precipitation
    • 5.1.2. Viral Inactivation Method
      • 5.1.2.1. pH Modification
      • 5.1.2.2. Solvent Detergent (S/D)
      • 5.1.2.3. Pasteurization
      • 5.1.2.4. Dry Heat
      • 5.1.2.5. Others
    • 5.1.3. Viral Detection Method
      • 5.1.3.1. Next Generation Sequencing (NGS)
      • 5.1.3.2. Polymerase Chain Reaction (PCR)
      • 5.1.3.3. In vivo Assay
      • 5.1.3.4. In vitro Assay
      • 5.1.3.5. Others
  • 5.2. Market Analysis, Insights and Forecast - By Applications
    • 5.2.1. Blood and Blood Products
    • 5.2.2. Recombinant Proteins
    • 5.2.3. Cellular & Gene Therapy Products
    • 5.2.4. Vaccines
    • 5.2.5. Others
  • 5.3. Market Analysis, Insights and Forecast - By End-user
    • 5.3.1. Pharmaceutical and Biotech Industry
    • 5.3.2. Academic Research Institutes
    • 5.3.3. CROs
    • 5.3.4. Others
  • 5.4. Market Analysis, Insights and Forecast - By Geography
    • 5.4.1. North America
    • 5.4.2. Europe
    • 5.4.3. Asia Pacific
    • 5.4.4. Latin America
    • 5.4.5. Middle East & Africa

6. North America Viral Clearance Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Method
    • 6.1.1. Viral Removal Method
      • 6.1.1.1. Chromatography
      • 6.1.1.2. Filtration
      • 6.1.1.3. Precipitation
    • 6.1.2. Viral Inactivation Method
      • 6.1.2.1. pH Modification
      • 6.1.2.2. Solvent Detergent (S/D)
      • 6.1.2.3. Pasteurization
      • 6.1.2.4. Dry Heat
      • 6.1.2.5. Others
    • 6.1.3. Viral Detection Method
      • 6.1.3.1. Next Generation Sequencing (NGS)
      • 6.1.3.2. Polymerase Chain Reaction (PCR)
      • 6.1.3.3. In vivo Assay
      • 6.1.3.4. In vitro Assay
      • 6.1.3.5. Others
  • 6.2. Market Analysis, Insights and Forecast - By Applications
    • 6.2.1. Blood and Blood Products
    • 6.2.2. Recombinant Proteins
    • 6.2.3. Cellular & Gene Therapy Products
    • 6.2.4. Vaccines
    • 6.2.5. Others
  • 6.3. Market Analysis, Insights and Forecast - By End-user
    • 6.3.1. Pharmaceutical and Biotech Industry
    • 6.3.2. Academic Research Institutes
    • 6.3.3. CROs
    • 6.3.4. Others
  • 6.4. Market Analysis, Insights and Forecast - By Country
    • 6.4.1. U.S.
    • 6.4.2. Canada

7. Europe Viral Clearance Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Method
    • 7.1.1. Viral Removal Method
      • 7.1.1.1. Chromatography
      • 7.1.1.2. Filtration
      • 7.1.1.3. Precipitation
    • 7.1.2. Viral Inactivation Method
      • 7.1.2.1. pH Modification
      • 7.1.2.2. Solvent Detergent (S/D)
      • 7.1.2.3. Pasteurization
      • 7.1.2.4. Dry Heat
      • 7.1.2.5. Others
    • 7.1.3. Viral Detection Method
      • 7.1.3.1. Next Generation Sequencing (NGS)
      • 7.1.3.2. Polymerase Chain Reaction (PCR)
      • 7.1.3.3. In vivo Assay
      • 7.1.3.4. In vitro Assay
      • 7.1.3.5. Others
  • 7.2. Market Analysis, Insights and Forecast - By Applications
    • 7.2.1. Blood and Blood Products
    • 7.2.2. Recombinant Proteins
    • 7.2.3. Cellular & Gene Therapy Products
    • 7.2.4. Vaccines
    • 7.2.5. Others
  • 7.3. Market Analysis, Insights and Forecast - By End-user
    • 7.3.1. Pharmaceutical and Biotech Industry
    • 7.3.2. Academic Research Institutes
    • 7.3.3. CROs
    • 7.3.4. Others
  • 7.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 7.4.1. U.K.
    • 7.4.2. Germany
    • 7.4.3. France
    • 7.4.4. Spain
    • 7.4.5. Italy
    • 7.4.6. Scandinavia
    • 7.4.7. Rest of Europe

8. Asia Pacific Viral Clearance Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Method
    • 8.1.1. Viral Removal Method
      • 8.1.1.1. Chromatography
      • 8.1.1.2. Filtration
      • 8.1.1.3. Precipitation
    • 8.1.2. Viral Inactivation Method
      • 8.1.2.1. pH Modification
      • 8.1.2.2. Solvent Detergent (S/D)
      • 8.1.2.3. Pasteurization
      • 8.1.2.4. Dry Heat
      • 8.1.2.5. Others
    • 8.1.3. Viral Detection Method
      • 8.1.3.1. Next Generation Sequencing (NGS)
      • 8.1.3.2. Polymerase Chain Reaction (PCR)
      • 8.1.3.3. In vivo Assay
      • 8.1.3.4. In vitro Assay
      • 8.1.3.5. Others
  • 8.2. Market Analysis, Insights and Forecast - By Applications
    • 8.2.1. Blood and Blood Products
    • 8.2.2. Recombinant Proteins
    • 8.2.3. Cellular & Gene Therapy Products
    • 8.2.4. Vaccines
    • 8.2.5. Others
  • 8.3. Market Analysis, Insights and Forecast - By End-user
    • 8.3.1. Pharmaceutical and Biotech Industry
    • 8.3.2. Academic Research Institutes
    • 8.3.3. CROs
    • 8.3.4. Others
  • 8.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 8.4.1. Japan
    • 8.4.2. China
    • 8.4.3. India
    • 8.4.4. Australia
    • 8.4.5. Southeast Asia
    • 8.4.6. Rest of Asia Pacific

9. Latin America Viral Clearance Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Method
    • 9.1.1. Viral Removal Method
      • 9.1.1.1. Chromatography
      • 9.1.1.2. Filtration
      • 9.1.1.3. Precipitation
    • 9.1.2. Viral Inactivation Method
      • 9.1.2.1. pH Modification
      • 9.1.2.2. Solvent Detergent (S/D)
      • 9.1.2.3. Pasteurization
      • 9.1.2.4. Dry Heat
      • 9.1.2.5. Others
    • 9.1.3. Viral Detection Method
      • 9.1.3.1. Next Generation Sequencing (NGS)
      • 9.1.3.2. Polymerase Chain Reaction (PCR)
      • 9.1.3.3. In vivo Assay
      • 9.1.3.4. In vitro Assay
      • 9.1.3.5. Others
  • 9.2. Market Analysis, Insights and Forecast - By Applications
    • 9.2.1. Blood and Blood Products
    • 9.2.2. Recombinant Proteins
    • 9.2.3. Cellular & Gene Therapy Products
    • 9.2.4. Vaccines
    • 9.2.5. Others
  • 9.3. Market Analysis, Insights and Forecast - By End-user
    • 9.3.1. Pharmaceutical and Biotech Industry
    • 9.3.2. Academic Research Institutes
    • 9.3.3. CROs
    • 9.3.4. Others
  • 9.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 9.4.1. Brazil
    • 9.4.2. Mexico
    • 9.4.3. Rest of Latin America

10. Middle East & Africa Viral Clearance Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Method
    • 10.1.1. Viral Removal Method
      • 10.1.1.1. Chromatography
      • 10.1.1.2. Filtration
      • 10.1.1.3. Precipitation
    • 10.1.2. Viral Inactivation Method
      • 10.1.2.1. pH Modification
      • 10.1.2.2. Solvent Detergent (S/D)
      • 10.1.2.3. Pasteurization
      • 10.1.2.4. Dry Heat
      • 10.1.2.5. Others
    • 10.1.3. Viral Detection Method
      • 10.1.3.1. Next Generation Sequencing (NGS)
      • 10.1.3.2. Polymerase Chain Reaction (PCR)
      • 10.1.3.3. In vivo Assay
      • 10.1.3.4. In vitro Assay
      • 10.1.3.5. Others
  • 10.2. Market Analysis, Insights and Forecast - By Applications
    • 10.2.1. Blood and Blood Products
    • 10.2.2. Recombinant Proteins
    • 10.2.3. Cellular & Gene Therapy Products
    • 10.2.4. Vaccines
    • 10.2.5. Others
  • 10.3. Market Analysis, Insights and Forecast - By End-user
    • 10.3.1. Pharmaceutical and Biotech Industry
    • 10.3.2. Academic Research Institutes
    • 10.3.3. CROs
    • 10.3.4. Others
  • 10.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 10.4.1. GCC
    • 10.4.2. South Africa
    • 10.4.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. Merck KGaA
      • 11.2.1.1. Overview
      • 11.2.1.2. Products & Services
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. Wuxi Biologics
      • 11.2.2.1. Overview
      • 11.2.2.2. Products & Services
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. Charles River Laboratories
      • 11.2.3.1. Overview
      • 11.2.3.2. Products & Services
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. Texcell
      • 11.2.4.1. Overview
      • 11.2.4.2. Products & Services
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. Vironova
      • 11.2.5.1. Overview
      • 11.2.5.2. Products & Services
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. Kedrion
      • 11.2.6.1. Overview
      • 11.2.6.2. Products & Services
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)
    • 11.2.7. Clean Cells
      • 11.2.7.1. Overview
      • 11.2.7.2. Products & Services
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. Financials (Based on Availability)
    • 11.2.8. ViruSure GmbH
      • 11.2.8.1. Overview
      • 11.2.8.2. Products & Services
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. Financials (Based on Availability)
    • 11.2.9. Sartorius AG
      • 11.2.9.1. Overview
      • 11.2.9.2. Products & Services
      • 11.2.9.3. SWOT Analysis
      • 11.2.9.4. Recent Developments
      • 11.2.9.5. Strategies
      • 11.2.9.6. Financials (Based on Availability)
    • 11.2.10. Syngene International Limited
      • 11.2.10.1. Overview
      • 11.2.10.2. Products & Services
      • 11.2.10.3. SWOT Analysis
      • 11.2.10.4. Recent Developments
      • 11.2.10.5. Strategies
      • 11.2.10.6. Financials (Based on Availability)
    • 11.2.11. Microbiologics
      • 11.2.11.1. Overview
      • 11.2.11.2. Products & Services
      • 11.2.11.3. SWOT Analysis
      • 11.2.11.4. Recent Developments
      • 11.2.11.5. Strategies
      • 11.2.11.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Viral Clearance Market Revenue (USD million) Forecast, by Method, 2021-2034
  • Table 2: Global Viral Clearance Market Revenue (USD million) Forecast, by Viral Removal Method, 2021-2034
  • Table 3: Global Viral Clearance Market Revenue (USD million) Forecast, by Viral Inactivation Method, 2021-2034
  • Table 4: Global Viral Clearance Market Revenue (USD million) Forecast, by Viral Detection Method, 2021-2034
  • Table 5: Global Viral Clearance Market Revenue (USD million) Forecast, by Application, 2021-2034
  • Table 6: Global Viral Clearance Market Revenue (USD million) Forecast, by End-user, 2021-2034
  • Table 7: Global Viral Clearance Market Revenue (USD million) Forecast, by Region, 2021-2034
  • Table 8: North America Viral Clearance Market Revenue (USD million) Forecast, by Method, 2021-2034
  • Table 9: North America Viral Clearance Market Revenue (USD million) Forecast, by Viral Removal Method, 2021-2034
  • Table 10: North America Viral Clearance Market Revenue (USD million) Forecast, by Viral Inactivation Method, 2021-2034
  • Table 11: North America Viral Clearance Market Revenue (USD million) Forecast, by Viral Detection Method, 2021-2034
  • Table 12: North America Viral Clearance Market Revenue (USD million) Forecast, by Application, 2021-2034
  • Table 13: North America Viral Clearance Market Revenue (USD million) Forecast, by End-user, 2021-2034
  • Table 14: North America Viral Clearance Market Revenue (USD million) Forecast, By Country, 2021-2034
  • Table 15: Europe Viral Clearance Market Revenue (USD million) Forecast, by Method, 2021-2034
  • Table 16: Europe Viral Clearance Market Revenue (USD million) Forecast, by Viral Removal Method, 2021-2034
  • Table 17: Europe Viral Clearance Market Revenue (USD million) Forecast, by Viral Inactivation Method, 2021-2034
  • Table 18: Europe Viral Clearance Market Revenue (USD million) Forecast, by Viral Detection Method, 2021-2034
  • Table 19: Europe Viral Clearance Market Revenue (USD million) Forecast, by Application, 2021-2034
  • Table 20: Europe Viral Clearance Market Revenue (USD million) Forecast, by End-user, 2021-2034
  • Table 21: Europe Viral Clearance Market Revenue (USD million) Forecast, By Country/ Sub-region, 2021-2034
  • Table 22: Asia Pacific Viral Clearance Market Revenue (USD million) Forecast, by Method, 2021-2034
  • Table 23: Asia Pacific Viral Clearance Market Revenue (USD million) Forecast, by Viral Removal Method, 2021-2034
  • Table 24: Asia Pacific Viral Clearance Market Revenue (USD million) Forecast, by Viral Inactivation Method, 2021-2034
  • Table 25: Asia Pacific Viral Clearance Market Revenue (USD million) Forecast, by Viral Detection Method, 2021-2034
  • Table 26: Asia Pacific Viral Clearance Market Revenue (USD million) Forecast, by Application, 2021-2034
  • Table 27: Asia Pacific Viral Clearance Market Revenue (USD million) Forecast, by End-user, 2021-2034
  • Table 28: Asia Pacific Viral Clearance Market Revenue (USD million) Forecast, By Country/ Sub-region, 2021-2034
  • Table 29: Latin America Viral Clearance Market Revenue (USD million) Forecast, by Method, 2021-2034
  • Table 30: Latin America Viral Clearance Market Revenue (USD million) Forecast, by Viral Removal Method, 2021-2034
  • Table 31: Latin America Viral Clearance Market Revenue (USD million) Forecast, by Viral Inactivation Method, 2021-2034
  • Table 32: Latin America Viral Clearance Market Revenue (USD million) Forecast, by Viral Detection Method, 2021-2034
  • Table 33: Latin America Viral Clearance Market Revenue (USD million) Forecast, by Application, 2021-2034
  • Table 34: Latin America Viral Clearance Market Revenue (USD million) Forecast, by End-user, 2021-2034
  • Table 35: Latin America Viral Clearance Market Revenue (USD million) Forecast, By Country/ Sub-region, 2021-2034
  • Table 36: Middle East & Africa Viral Clearance Market Revenue (USD million) Forecast, by Method, 2021-2034
  • Table 37: Middle East & Africa Viral Clearance Market Revenue (USD million) Forecast, by Viral Removal Method, 2021-2034
  • Table 38: Middle East & Africa Viral Clearance Market Revenue (USD million) Forecast, by Viral Inactivation Method, 2021-2034
  • Table 39: Middle East & Africa Viral Clearance Market Revenue (USD million) Forecast, by Viral Detection Method, 2021-2034
  • Table 40: Middle East & Africa Viral Clearance Market Revenue (USD million) Forecast, by Application, 2021-2034
  • Table 41: Middle East & Africa Viral Clearance Market Revenue (USD million) Forecast, by End-user, 2021-2034
  • Table 42: Middle East & Africa Viral Clearance Market Revenue (USD million) Forecast, By Country/ Sub-region, 2021-2034

List of Figures

  • Figure 01: Global Viral Clearance Market Revenue Breakdown (USD million, %) by Region, 2025 & 2034
  • Figure 01: Global Viral Clearance Market Value Share (%), By Method, 2025 & 2034
  • Figure 02: Global Viral Clearance Market Value Share (%), By Application, 2025 & 2034
  • Figure 03: Global Viral Clearance Market Value Share (%), By End-user, 2025 & 2034
  • Figure 04: Global Viral Clearance Market Value Share (%), By Region, 2025 & 2034
  • Figure 05: North America Viral Clearance Market Value (USD million), By Method, 2025 & 2034
  • Figure 06: North America Viral Clearance Market Value Share (%), By Method, 2025
  • Figure 07: North America Viral Clearance Market Value (USD million), By Application, 2025 & 2034
  • Figure 08: North America Viral Clearance Market Value Share (%), By Application, 2025
  • Figure 09: North America Viral Clearance Market Value (USD million), By End-user, 2025 & 2034
  • Figure 10: North America Viral Clearance Market Value Share (%), By End-user, 2025
  • Figure 11: North America Viral Clearance Market Value (USD million), By Region, 2025 & 2034
  • Figure 12: North America Viral Clearance Market Value Share (%), By Region, 2025
  • Figure 13: Europe Viral Clearance Market Value (USD million), By Method, 2025 & 2034
  • Figure 14: Europe Viral Clearance Market Value Share (%), By Method, 2025
  • Figure 15: Europe Viral Clearance Market Value (USD million), By Application, 2025 & 2034
  • Figure 16: Europe Viral Clearance Market Value Share (%), By Application, 2025
  • Figure 17: Europe Viral Clearance Market Value (USD million), By End-user, 2025 & 2034
  • Figure 18: Europe Viral Clearance Market Value Share (%), By End-user, 2025
  • Figure 19: Europe Viral Clearance Market Value (USD million), By Country/Sub-region, 2025 & 2034
  • Figure 20: Europe Viral Clearance Market Value Share (%), By Country/Sub-region, 2025
  • Figure 21: Asia Pacific Viral Clearance Market Value (USD million), By Method, 2025 & 2034
  • Figure 22: Asia Pacific Viral Clearance Market Value Share (%), By Method, 2025
  • Figure 23: Asia Pacific Viral Clearance Market Value (USD million), By Application, 2025 & 2034
  • Figure 24: Asia Pacific Viral Clearance Market Value Share (%), By Application, 2025
  • Figure 25: Asia Pacific Viral Clearance Market Value (USD million), By End-user, 2025 & 2034
  • Figure 26: Asia Pacific Viral Clearance Market Value Share (%), By End-user, 2025
  • Figure 27: Asia Pacific Viral Clearance Market Value (USD million), By Country/Sub-region, 2025 & 2034
  • Figure 28: Asia Pacific Viral Clearance Market Value Share (%), By Country/Sub-region, 2025
  • Figure 29: Latin America Viral Clearance Market Value (USD million), By Method, 2025 & 2034
  • Figure 30: Latin America Viral Clearance Market Value Share (%), By Method, 2025
  • Figure 31: Latin America Viral Clearance Market Value (USD million), By Application, 2025 & 2034
  • Figure 32: Latin America Viral Clearance Market Value Share (%), By Application, 2025
  • Figure 33: Latin America Viral Clearance Market Value (USD million), By End-user, 2025 & 2034
  • Figure 34: Latin America Viral Clearance Market Value Share (%), By End-user, 2025
  • Figure 35: Latin America Viral Clearance Market Value (USD million), By Country/Sub-region, 2025 & 2034
  • Figure 36: Latin America Viral Clearance Market Value Share (%), By Country/Sub-region, 2025
  • Figure 37: Middle East & Africa Viral Clearance Market Value (USD million), By Method, 2025 & 2034
  • Figure 38: Middle East & Africa Viral Clearance Market Value Share (%), By Method, 2025
  • Figure 39: Middle East & Africa Viral Clearance Market Value (USD million), By Application, 2025 & 2034
  • Figure 40: Middle East & Africa Viral Clearance Market Value Share (%), By Application, 2025
  • Figure 41: Middle East & Africa Viral Clearance Market Value (USD million), By End-user, 2025 & 2034
  • Figure 42: Middle East & Africa Viral Clearance Market Value Share (%), By End-user, 2025
  • Figure 43: Middle East & Africa Viral Clearance Market Value (USD million), By Country/Sub-region, 2025 & 2034
  • Figure 44: Middle East & Africa Viral Clearance Market Value Share (%), By Country/Sub-region, 2025
  • Figure 45: Global Viral Clearance Market Share (%), By Company, 2025